Patient Support

From ensuring your eligible patients have access to EYLEA to helping them navigate reimbursement, EYLEA4U^® is here to help.

Did you know?¹

An estimated 9 million doses of EYLEA have been administered to ≈790,000 eyes since launch (and counting)¹
Patients received more than $60 million in commercial copay support in 2019

EYLEA4U has support for all eligible patients

EYLEA4U is committed to help ensure your eligible patients have access to EYLEA for the treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion (MEfRVO), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR). Our programs include*:

Copay card program for EYLEA cost assistance.

EYLEA Copay Card Program

With the EYLEA Copay Card, patients with commercial healthcare coverage may be eligible to pay as little as a $0 copay for each EYLEA treatment.^†,‡ Subject to annual assistance limit.

See the program

Eligible patients can receive EYLEA at no cost.

Patient Assistance Program

No insurance or no coverage for EYLEA? No problem. The Patient Assistance Program (PAP) from EYLEA4U can provide EYLEA free of charge to eligible patients.^II

Get more information

Alternate Coverage Referral

EYLEA4U can provide
information about the referral process, which connects patients in need to independent charitable foundations.^§

Learn about the process

*Program conditions apply.
^†Patients will be responsible for any additional copay costs that exceed the annual assistance limit.
^‡Subject to annual assistance limit. Not an insurance or debit card program. This program is not valid for prescriptions covered by or submitted for reimbursement under Medicaid, Medicare, VA, DOD, TRICARE, or similar federal or state programs. This program does not cover or provide support for supplies, procedures, or any physician-related service associated with EYLEA. General, non–product-specific copay, coinsurance, or insurance deductibles are not covered. This program is not valid where prohibited by law, taxed, or restricted. EYLEA4U reserves the right to rescind, revoke, terminate, or amend this offer, eligibility, and terms of use at any time without notice. Additional program conditions apply.
^§Regeneron does not influence or control the operations of independent charitable foundations and cannot guarantee assistance will be provided. Subject to Regeneron policies.
^IIHousehold income limits apply.

Did you know? More than 39,000 patients

received support through the EYLEA Commercial Copay Card Program in 2018.*

*EYLEA4U EBR Report 2019.

Find the right copay support for your patients

Follow this flowchart to determine how to connect your patients to the right program for help with out-of-pocket costs.

The EYLEA4U Enrollment Form is completed and Copay Card Program/Alternate Coverage Referral is selected.

EYLEA4U verifies benefits and whether patient has
an out-of-pocket cost for EYLEA.

Is patient insured by a commercial
or private insurer?

EYLEA Copay Card Program
Eligible patients who have commercial insurance, not funded through a government healthcare program, may qualify for help with their EYLEA out-of-pocket copay costs..

YES

Alternate Coverage Referral
For patients who need help with their out-of-pocket costs, EYLEA4U can assist with the referral process to an independent charitable foundation for approved indications.*

EYLEA® (aflibercept) Injection out-of-pocket costs flowchart.

*Regeneron does not influence or control the operations of independent charitable foundations and cannot guarantee assistance will be provided.

EYLEA4U Enrollment Form

Complete the EYLEA4U Enrollment Form to begin the process of helping your patients determine copay assistance eligibility.

Experience what certain retinal diseases can be like in virtual reality

Retinal disease virtual and augmented reality app.

A powerful tool to use with your patients and caregivers, this unique app lets the user experience symptoms of degenerative eye disease, such as diabetic retinal changes, firsthand in a 360° view. In My Eyes uses virtual reality and augmented reality to show the impact of vision impairment on everyday situations.

Product Support

Find complete product support—
guiding you through
orders, returns, and more.

Learn how it works

Reimbursement Support

Get information about navigating the
reimbursement process. Find enrollment forms, learn about PA assistance, and more.

See the details

Resources

Get the information you
and your patients need
about EYLEA.

See resources

See More Important Safety Information and Indications

CONTRAINDICATIONS: EYLEA is contraindicated in patients with ocular or periocular infections, active intraocular inflammation, or known hypersensitivity to aflibercept or to any of the excipients in EYLEA.

Important Safety Information

CONTRAINDICATIONS

EYLEA is contraindicated in patients with ocular or periocular infections, active intraocular inflammation, or known hypersensitivity to aflibercept or to any of the excipients in EYLEA.

WARNINGS AND PRECAUTIONS

Intravitreal injections, including those with EYLEA, have been associated with endophthalmitis and retinal detachments. Proper aseptic injection technique must always be used when administering EYLEA. Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay and should be managed appropriately. Intraocular inflammation has been reported with the use of EYLEA.
Acute increases in intraocular pressure have been seen within 60 minutes of intravitreal injection, including with EYLEA. Sustained increases in intraocular pressure have also been reported after repeated intravitreal dosing with VEGF inhibitors. Intraocular pressure and the perfusion of the optic nerve head should be monitored and managed appropriately.
There is a potential risk of arterial thromboembolic events (ATEs) following intravitreal use of VEGF inhibitors, including EYLEA. ATEs are defined as nonfatal stroke, nonfatal myocardial infarction, or vascular death (including deaths of unknown cause). The incidence of reported thromboembolic events in wet AMD studies during the first year was 1.8% (32 out of 1824) in the combined group of patients treated with EYLEA compared with 1.5% (9 out of 595) in patients treated with ranibizumab; through 96 weeks, the incidence was 3.3% (60 out of 1824) in the EYLEA group compared with 3.2% (19 out of 595) in the ranibizumab group. The incidence in the DME studies from baseline to week 52 was 3.3% (19 out of 578) in the combined group of patients treated with EYLEA compared with 2.8% (8 out of 287) in the control group; from baseline to week 100, the incidence was 6.4% (37 out of 578) in the combined group of patients treated with EYLEA compared with 4.2% (12 out of 287) in the control group. There were no reported thromboembolic events in the patients treated with EYLEA in the first six months of the RVO studies.

ADVERSE REACTIONS

Serious adverse reactions related to the injection procedure have occurred in <0.1% of intravitreal injections with EYLEA including endophthalmitis and retinal detachment.
The most common adverse reactions (≥5%) reported in patients receiving EYLEA were conjunctival hemorrhage, eye pain, cataract, vitreous detachment, vitreous floaters, and intraocular pressure increased.

INDICATIONS

EYLEA^® (aflibercept) Injection 2 mg (0.05 mL) is indicated for the treatment of patients with Neovascular (Wet) Age-related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR).

Please see the full Prescribing Information for EYLEA.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

The information provided in this site is intended only for healthcare professionals in the United States. The products discussed herein may have different product labeling in different countries.

Reference

Data on file. Regeneron Pharmaceuticals, Inc.

EYLEA and EYLEA4U are registered trademarks of Regeneron Pharmaceuticals, Inc.

10/2020
EYL.20.10.0001